Abstract
The role of integrins is important for tumor proliferation, angiogenesis, invasion and metastasis. Integrins are the principal receptors for binding most extracellular matrix (ECM) proteins. Integrins serve two major roles in cell function: cell adhesion and cell signaling. There are multiple mechanisms by which integrins can be assessed in the laboratory, and clinical trials with anti-integrin antibodies are ongoing. Tumor cells can use variable integrin expression to increase proliferation and promote metastasis and angiogenesis. There may be a role for integrin blockade in the treatment of tumor growth and metastasis, though successful human trials have not yet been achieved.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alberts B, Johnson A, Lewis J. Integrins. Molecular biology of the cell. In: B Alberts (eds), 4th ed. New York: Garland; 2002.
Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther. 2012;12:251–7.
Barkan D, Chambers AF. beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res. 2011;17:7219–23.
Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.
Danen EHJ. Integrin signaling as a cancer drug target. ISRN Cell Biol. 2013;2013:1–14.
Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 2012;9:2961–73.
Dearling JL, Park EJ, Dunning P, Baker A, Fahey F, Treves ST, et al. Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. Inflamm Bowel Dis. 2010;16:1458–66.
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
Garmy-Susini B. Integrin signaling in lymphangiogenesis. In: Bagley RG, editor. The tumor microenvironment. New York: Humana Press; 2010. p. 289–310.
Gu X, Xing X, Yang W, Hu J, Dai D. High expression of integrin-linked kinase predicts aggressiveness and poor prognosis in patients with gastric cancer. Acta Histochem. 2014;116:758–62.
Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5:816–26.
Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human alphanu integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2013;24:329–36.
Hudson LG, Stack MS. Integrins and cancer. In: Bagley RG, editor. The tumor microenvironment. New York: Humana Press; 2010. p. 509–30.
Marciano DK, Denda S, Reichardt LF. Methods for identifying novel integrin ligands. Methods Enzymol. 2007;426:223–37.
Masur SK, Cheung JK, Antohi S. Identification of integrins in cultured corneal fibroblasts and in isolated keratocytes. Invest Ophthalmol Vis Sci. 1993;34:2690–8.
Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 2011;1:35.
Morales-Avila E, Ferro-Flores G, Ocampo-Garcia BE, Gomez-Olivan LM. Engineered multifunctional RGD-gold nanoparticles for the detection of tumour-specific alpha(v)beta(3) expression: chemical characterisation and ecotoxicological risk assessment. J Biomed Nanotechnol. 2012;8:991–9.
O’Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, et al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011;105:346–52.
Plopper G. Chapter 19: The extracellular amtrix and cell adhesion. In: Cassimeris L, Lingappa VR, editors. Lewin’s cells. Massachusetts: Jones and Bartlett; 2011. p. 821–80.
Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610–7.
Shuhendler AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY. A novel solid lipid nanoparticle formulation for active targeting to tumor alpha(v) beta(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater. 2012;1:600–8.
Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712–8.
Stupp R, Hegi ME, Gorlia T, Erridge S, Perry J, Hong Y, Aldape KD, Lhermitte B, Pietsch T, Grujicic D. S Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1100–8.
Trajkovic-Arsic M, Mohajerani P, Sarantopoulos A, Kalideris E, Steiger K, Esposito I, et al. Multimodal molecular imaging of integrin alphavbeta3 for in vivo detection of pancreatic cancer. J Nucl Med. 2014;55:446–51.
Wu H, Chen H, Sun Y, Wan Y, Wang F, Jia B, et al. Imaging integrin alpha(v)beta(3) positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake. Cancer Lett. 2013;335:75–80.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this entry
Cite this entry
de Moll, E.H., Dong, J., Oliva, M., Saenger, Y. (2017). Integrins, Immunology. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_131
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0717-2_131
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0716-5
Online ISBN: 978-1-4419-0717-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences